Retention of clinical biosamples / blank matrices [Regulatives / Guidelines]

posted by Ohlbe – France, 2019-04-24 13:54 (2058 d 01:51 ago) – Posting: # 20219
Views: 3,298

Hi John,

❝ Do you know why some sponsors want to have their samples kept until application approved?


"Because we've always done it", I guess...

❝ From EMA or FDA, is there a requirement mentioned in any of the guidances?


EMA: no. FDA: not that I know of.

❝ We are doing this (store samples) as well and I wonder why we need to if the age of the samples exceeds the long term stability date.


I agree with ElMaestro: some sponsors just want to be on the safe side and only repeat the bioanalytical part rather than the whole study if the lab messed up somewhere. There was a time also when guidelines or requirements were not as clear as they can be now and an Agency would unexpectedly ask for the metabolite in addition to the parent, or similar stuff.
—
Regards
Ohlbe

Complete thread:

UA Flag
Activity
 Admin contact
23,336 posts in 4,902 threads, 1,666 registered users;
32 visitors (1 registered, 31 guests [including 9 identified bots]).
Forum time: 14:46 CET (Europe/Vienna)

I’m all in favor of the democratic principle
that one idiot is as good as one genius, but I draw the line
when someone takes the next step and concludes
that two idiots are better than one genius.    Leo Szilard

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5